Hernàndez-Pando Rogelio, Castañòn Mauricio, Espitia Clara, Lopez-Vidal Yolanda
Experimental Pathology Section, Department of Pathology, National Institute of Medical Sciences and Nutrition Salvador Zubiràn, Mexico City, Mexico.
Curr Mol Med. 2007 Jun;7(4):365-72. doi: 10.2174/156652407780831610.
Given the variable protective efficacy provided by Mycobacterium bovis BCG (Bacillus Calmette-Guérin), there is a concerted effort worldwide to develop better vaccines that could be used to reduce the burden of tuberculosis. Recombinant BCG (rBCG) are vaccine candidates that offer some potential in this area. In this paper, we will discuss the molecular methods used to generate rBCG, and the results obtained with some of these new vaccines as compared with the conventional BCG vaccine in diverse animal models. Tuberculosis vaccine candidates based on rBCG are promising candidates, and some of them are now being tested in clinical trials.
鉴于牛分枝杆菌卡介苗（Bacillus Calmette-Guérin）所提供的保护效力存在差异，全球正在齐心协力研发更有效的疫苗，以减轻结核病负担。重组卡介苗（rBCG）是在这一领域具有一定潜力的候选疫苗。在本文中，我们将讨论用于制备rBCG的分子方法，以及与传统卡介苗疫苗相比，其中一些新疫苗在不同动物模型中所获得的结果。基于rBCG的结核病候选疫苗前景广阔，其中一些正在进行临床试验。
